FMP
May 15, 2024 9:00 AM - Gordon Thompson
Image credit: Google Images
Plus Therapeutics, Inc. (NASDAQ:PSTV), a clinical-stage pharmaceutical company, is gearing up to share its quarterly earnings on Thursday, May 16, 2024, after the market closes. Specializing in the development of targeted radiotherapeutics for central nervous system cancers, PSTV's financial performance is closely watched by investors and analysts alike. The anticipation builds around the earnings per share (EPS) forecasted at -$0.25 and expected revenue of approximately $1.69 million for the quarter.
The upcoming earnings report follows a period where PSTV reported revenue of $1.31 million with a gross profit of $1.13 million. This financial snapshot indicates a company that, despite its challenges, is managing to generate revenue and maintain a certain level of gross profit. The cost of revenue standing at $182,000 for the same period further highlights the company's ability to control its production or service delivery costs, an essential factor for its financial health.
However, PSTV's financial journey is not without its hurdles. The company faced a significant net income loss of -$3.81 million and an operating income loss of -$3.86 million. These figures point to the challenges PSTV encounters in balancing its operational costs against its revenue. The reported EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of -$3.68 million further underscores the financial strains the company is experiencing, reflecting broader operational challenges beyond mere net income figures.
Moreover, the earnings per share (EPS) for the quarter was reported at -$0.84, a critical metric for investors as it provides a direct insight into the company's profitability on a per-share basis. This figure is particularly significant when compared to the upcoming earnings forecast, which estimates the EPS to be -$0.25. The improvement in EPS, if realized, could signal a positive shift in PSTV's financial trajectory, offering a glimmer of hope for stakeholders looking for signs of recovery and growth.
As PSTV prepares to unveil its first quarter financial results for 2024, the management team plans to host a conference call and webcast to discuss the outcomes and provide updates on the company's operations. This event is not only a platform for financial disclosures but also an opportunity for PSTV to articulate its strategic direction and operational updates, offering a comprehensive view of its path forward in the competitive pharmaceutical landscape.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 16, 2024 8:06 PM - Gordon Thompson
On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...